FDA Acceptance of NDA for Tiopronin by Casper Pharma
The FDA has accepted the New Drug Application (NDA) 212927 for Tiopronin submitted by Casper Pharma, indicating a standard review process.
Asset / Drug
Drug and asset intelligence for Tiopronin with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.